3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
pembrolizumab
51
Ipilimumab
49
Cyclophosphamide
43
Nivolumab
40
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
spartalizumab
9
cobimetinib
9
binimetinib
9
Radiotherapy
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts